Key clinical point: Sulindac relieved musculoskeletal symptoms in patients with hormone receptor-positive (HR+) breast cancer (BC) who received aromatase inhibitor (AI) for ≥3 months.
Major finding: At 12 months, patients receiving sulindac reported a significant improvement in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; − 5.85; P = .003), pain (−5.40; P = .043), stiffness (−9.53, P < .001), and physical function (− 5.61; P = .006) with 37% of patients with higher baseline symptoms reporting ≥50% improvement in total WOMAC along with an overall tolerable safety profile.
Study details: Findings are from a phase 2 study of postmenopausal women with HR+ BC stable on AI therapy for ≥3 months, of which 43 women received 150 mg sulindac twice daily for 12 months whereas 40 women formed the non-randomized control arm.
Disclosures: This study was supported by the US National Cancer Institute. The authors declared no conflicts of interest.
Source: Martinez JA et al. Breast Cancer Res Treat. 2022;192:113-122 (Jan 18). Doi: 10.1007/s10549-021-06485-0.